This website is intended for UK healthcare professionals only Log in | Register

Editorial articles

January 2006 Br J Cardiol 2006;13:5-6

EDTA chelation therapy meets evidence-based medicine

Gervasio A Lamas, Steven J Hussein

Abstract

According to World Health Organization estimates, 16.7 million people die of cardiovascular diseases each year. By the year 2010, it is estimated that cardiovascular disease will become the leading cause of death in developing countries and by 2020 it will contribute to nearly 25 million deaths worldwide. Although therapies including drugs, lifestyle modification and revascularisation procedures have been demonstrated in clinical trials to be beneficial, they are under-utilised. Paradoxically, in spite of the under-use of evidence-based therapies, patients actively seek complemen- tary and alternative medicine (CAM) treatments. While many alternative therapies involve oral vitamin and mineral supple- ments that are unlikely to cause harm, chelation therapy is one of the most aggressive and intensive CAM modalities.

| Full text

January 2006 Br J Cardiol 2006;13:9-12

The emerging role of vitamin D and its receptor in the pathogenesis of acute coronary syndromes

Khalid Barakat, Graham A Hitman

Abstract

Our understanding of the pathophysiology of acute coronary syndromes and, in particular, the interplay of a number of complex parallel processes, continues to develop.1 These processes include inflammation, thrombosis and matrix turnover with potential gene and environmental influences. Vitamin D, known primarily as a hormone of bone metabolism, can affect the transcription of a number of genes which play a pivotal role in both the development of acute coronary syndromes and the pathogenesis of coronary artery disease (CAD). The purpose of this review is to examine the mechanisms by which vitamin D and the vitamin D receptor (VDR) might influence the development of acute coronary syndromes.

| Full text

November 2005 Br J Cardiol 2005;12:439-40

The oblique view

Michael Norell

Abstract

We continue our series where Consultant Interventionist Dr Michael Norell takes a sideways look at life in the
cath lab ….. and beyond. In this column, he looks at the unreal and riveting world of TV medicine.

| Full text

November 2005 Volume 12, Issue 6

The new GMS contract QOF update – hot tips and political hot potatoes

Sarah Jarvis

Abstract

Submissions are in and now the real lobbying can begin.
Scarcely a year after the implementation of the Quality
and Outcomes Framework (QOF) of the new General
Medical Services (GMS) contract,1 the first review is already
well underway and due to come into effect on 1st April 2006.

| Full text

November 2005 Br J Cardiol 2005;12:409-10

Combating vascular disease in Scotland

Alan G Begg

Abstract

As an organisation we are delighted that, as from this
issue, The British Journal of Cardiology will become
the official journal of the Scottish Heart and Arterial
Risk Prevention group (SHARP). SHARP, a registered charity
launched in Scotland in 1988, now attracts members from
across the UK bringing together a wide range of healthcare
professionals interested in the prevention and management
of cardiovascular disease (CVD).

| Full text

September 2005 Br J Cardiol 2005;12:336-8

ASCOT – hold on to your horses!

Bryan Williams

Abstract

The Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) reported the final results of its blood pressure
lowering arm at the European Society of Cardiology
(ESC) Annual meeting amidst much publicity.

| Full text

September 2005 Br J Cardiol 2005;12:333-5

Current and future status of left ventricular assist devices in the UK

Emma J Birks

Abstract

Heart failure affects over 750,000 people in the UK and
65,000 new cases are diagnosed every year. It carries a
poor prognosis with a population-based study finding
a 40% one-year mortality in all new diagnosed cases1 with
those in New York Heart Association (NYHA) class IV having a
60% one-year mortality.

| Full text

July 2005 Br J Cardiol (Acute Interv) Cardiol 2005;12:AIC 42–AIC 44

Are drug-eluting stents living up to the hype?

Adrian P Banning

Abstract

Drug-eluting stents (DES) have been available commercially in the UK for over three years. The National Institute for Clinical Excellence (NICE) produced a technology appraisal in October 2003 and that initial review is about to be updated. Well, has this technology delivered on its promise? Have we embraced it too quickly or is 100% DES usage around the corner?

| Full text

July 2005 Br J Cardiol 2005;12:255-6

What’s in a name? From anticoagulation clinics to thrombosis management centres

David A Fitzmaurice

Abstract

The association between mitral valve disease, atrial
fibrillation (AF) and the incidence of embolic stroke is well
known. The incidence of systemic embolism (including
embolic stroke) is seven times greater in patients with mitral
valve disease and AF.

| Full text

July 2005 Br J Cardiol 2005;12:249-53

Fat and visceral fat: time for cardiologists to act against obesity

Michael EJ Lean, Thang S Han

Abstract

Health risk is not synonymous with obesity and
obesity is not synonymous with visceral fat.
Obesity is now recognised by governments, and
importantly in medical training, as a chronic disease
leading to multiple organ-specific pathologies
(including metabolic syndrome and coronary heart disease).

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now